Incidence of malignancy after pediatric kidney transplantation: a single-center experience over the past three decades in Japan

Yujiro Aoki¹,² · Hiroyuki Satoh¹ · Yuko Hamasaki²,³ · Riku Hamada³ · Ryoko Harada³ · Hiroshi Hataya³,⁴ · Kenji Ishikura³,⁵ · Masaki Muramatsu² · Seiichiro Shishido² · Ken Sakai²

Received: 26 May 2021 / Accepted: 23 September 2021 / Published online: 27 September 2021
© The Author(s) 2021

Abstract

Background Malignancy after kidney transplantation (KT) is one of the most serious post-transplant complications. This study aimed to investigate the incidence, type, and outcomes of malignancy after pediatric KT.

Methods We performed a retrospective cohort study on pediatric kidney transplant recipients aged 18 years or younger who received their first transplant between 1975 and 2009.

Results Among the 375 children who underwent KT, 212 were male (56.5%) and 163 were female (43.5%) (median age at KT, 9.6 years [interquartile range {IQR}] 5.8–12.9 years). The incidence of malignancy was 5.6% (n = 21). The cumulative incidences of cancer were 0.8%, 2.5%, 2.8%, 4.2%, 5.5%, and 15.6% at 1, 5, 10, 15, 20, and 30 years post-transplantation, respectively. Of 375 patients, 12 (3.2%) had solid cancer and nine (2.4%) had lymphoproliferative malignancy. The median age at the first malignancy was 21.3 years (IQR 11.5–33.3 years). The median times from transplant to diagnosis were 22.3 years (IQR 12.3–26.6 years) for solid cancer and 2.2 years (IQR 0.6–2.8) for lymphoproliferative malignancies. During follow-up, five recipients died due to malignancy. The causes of death were hepatocellular carcinoma in one patient, squamous cell carcinoma in one patient, malignant schwannoma in one patient, and Epstein-Barr virus-related lymphoma in two patients. The mortality rate was 0.79 per 1000 person-years (95% confidence interval 0.38, 1.85).

Conclusions Early diagnosis and treatment of malignancies in transplant recipients is an important challenge. Therefore, enhanced surveillance and continued vigilance for malignancy following KT are necessary.

Keywords Kidney transplantation · Pediatric · Malignancy · Post-transplantation lymphoproliferative disease

Introduction

End-stage kidney failure is a rare and severe condition in children. Approximately 5–10 children per million in the age-related population start renal replacement therapy each year, and the mortality rate in children with end-stage kidney failure may be 30 times higher than that in the healthy age-related population [1, 2]. Pediatric kidney transplantation (KT) has become a standard renal replacement therapeutic option for chronic kidney disease (CKD), and the development and clinical application of new immunosuppressive agents has greatly improved KT outcomes, making it a well-established therapy [1]. Among the complications after KT, it is important to control cardiovascular diseases, infections, and malignancies that directly affect the prognosis of life. In this context, immunosuppressive therapy has been shown to increase the incidence of malignancy after KT [3].
Despite advances in immunosuppressants, patients who undergo pediatric KT have a five to ten times higher relative risk of cancer in the general population [4], and mortality due to malignancy after KT is ~11–18% [5, 6]. In particular, although calcineurin inhibitors, such as cyclosporin (CyA) and tacrolimus (Tac), have improved transplantation performance, post-transplant lymphoproliferative disease (PTLD) associated with Epstein–Barr virus (EBV) infection has increased [6]. Risk factors for PTLD include transplantation from an EBV-positive donor to an EBV-naive recipient, younger age at KT, and more aggressive immunosuppression. PTLDs are most likely to develop within the first year after transplantation [7, 8], and the incidence of PTLD in KT is reported to be 1.3% within 1 year and 2.4% within 5 years in children [9]. Furthermore, as post-transplant outcomes improve with long-term graft survival, indiscriminate and prolonged use of immunosuppressive drugs may not only cause various complications but also increase the risk of malignancy development; therefore, monitoring malignancies is an important issue.

The incidence and type of malignancy vary in different countries, and most reports are from Western countries. This study aimed to investigate the incidence, type, and outcomes of malignancies after pediatric KT at a single center in Japan.

Materials and methods

Ethics statements

This study was approved by the Research Ethics Committee (number H29b-91) before study commencement and complied with the Helsinki Declaration. The requirement for informed consent was waived by the committee.

Study design and data collection

We performed a retrospective cohort study of consecutive pediatric patients who underwent primary KT from January 1975 to December 2009 at Tokyo Metropolitan Kiyose Children’s Hospital (predecessor of Tokyo Metropolitan Children’s Medical Center). During this period, 375 patients underwent primary KT at the age of ≤ 18 years. The patients were followed up from their KT to the last date that they were confirmed to be alive as of December 2016. Clinical data were collected from the medical records and included information on patient and donor characteristics, medical history, physical examination findings, immunosuppressive drugs used, type of malignancy, date of malignancy development, patient and graft survival, cause of death, and graft loss. The patients were divided into two groups based on the development of cancer, and the two groups were compared.

Immunosuppression

The immunosuppressive protocol was divided into three periods. From 1975 to 1985 (era 1), the immunosuppressive protocol consisted of methylprednisolone (MPL), azathioprine (AZA), and/or mizoribine (MZ). In era 2, from 1986 to 2001, with the advent of CyA and Tac, the immunosuppressive protocol consisted of triple immunosuppression with MPL, AZA or MZ, and CyA or Tac. CyA and Tac were generally alternated in patients rather than randomized. Since 2002 (era 3), new immunosuppression regimes were introduced. Standard immunosuppression consisted of induction with basiliximab and triple therapy with MPL, CyA or Tac, and mycophenolate mofetil (MMF) [10]. CyA and Tac were generally alternated in patients rather than randomized. ABO-incompatible KT recipients underwent splenectomy at the time of KT, and rituximab was not used for B-cell depletion [11].

Statistical analysis

To avoid potential selection bias, the study protocol was designed and approved before data collection began. Although the sample size was not predetermined, it was comparable to those commonly employed in similar studies. In addition, to avoid information bias, variables with missing values were excluded from the analysis.

All continuous data were checked for normality using the Shapiro–Wilk test. Categorical data are expressed as a number with a percentage, and continuous data are expressed as the mean ± standard deviation and median with a range or interquartile range (IQR), depending on the normality of the distribution. Categorical clinical variables were analyzed using the Pearson chi-square test or Fisher’s exact test. Continuous variables were analyzed using the Student t test, and qualitative variables were analyzed using the Mann–Whitney U test. Patient and graft survival were estimated using the Kaplan–Meier method and compared using the log-rank test and generalized Wilcoxon test. Factors associated with the incidence of malignancy were assessed using univariate and multivariate analyses according to a Cox proportional hazards model. Variables with a P value <0.1 in the univariate analysis were included in the multivariate analysis. Multicollinearity between variables was evaluated using the variance inflation factor (VIF), with VIF > 10 signaling multicollinearity. The results are expressed as two-sided P-values, with P < 0.05 considered statistically significant.
Statistical analyses were performed using SPSS software (version 26.0; IBM Corp., Armonk, NY, USA).

Results

During the follow-up period, 21 patients with post-transplant malignancy (PTM) were reported among 375 patients, with a crude rate of 5.6%. The cumulative incidences of PTM were 0.8% ± 0.5% at 1 year post-KT (360 patients at risk), 2.5% ± 0.8% at 5 years post-KT (343 patients at risk), 2.8% ± 0.9% at 10 years post-KT (281 patients at risk), 4.2% ± 1.2% at 15 years post-KT (187 patients at risk), 5.5% ± 1.5% at 20 years post-KT (114 patients at risk), and 15.6% ± 4.8% at 30 years post-KT (30 patients at risk) (Fig. 1). In the development of malignancy during the follow-up period, 6017.2 person-years were observed. The morbidity rate per 1000 person-years was 3.49 (95% confidence interval [CI] 2.28, 5.34).

The characteristics of the study population are summarized in Table 1. The cancer group showed a significant difference in recipient sex and donor type compared to the non-cancer group. There were no ABO-incompatible KTs in the cancer group. The median age at the first malignancy was 21.3 years (IQR 11.5–33.3 years). The median follow-up period was 15.2 years (IQR, 10.6–29.6 years). There were 12 patients (3.2%) with solid cancer and nine patients (2.4%) with PTLD during the observation period.

Fig. 1 Estimated cumulative incidence of post-transplant malignancy after kidney transplant. Data shows the number of subjects at 0, 10, 20, 30, and 40 years post-transplant who were still at risk, and the cumulative number of subjects diagnosed with a PTM in our sample at those time points.

Individual characteristics of patients with solid cancers are shown in Table 2. The median time from transplant to diagnosis of malignancy was 22.3 years (IQR 12.3–26.6 years) for solid cancer. In the case of Denys–Drash syndrome (case 12), upper mediastinal lymph node metastasis was observed at 4.8 years, and lung metastasis at 7.2 years after KT, both of which remitted with chemotherapy. This case started with a unilateral Wilms tumor, which metastasized to the lung at 10 months even after completion of chemotherapy for the primary disease. Three patients (25%) died of malignancy. The patient survival rate after treatment for solid cancer was 75% during the follow-up period.

The characteristics of patients with PTLD are shown in Table 3. The median time from transplant to diagnosis was 2.2 years (IQR 0.6–2.8 years) for PTLD. All patients were treated with calcineurin inhibitors, and five patients (56%) were treated for acute rejection (AR) within 1 year after KT. Pre-transplantation EBV serology data in recipients and donors were not available in many cases. Pre-transplantation positive EBV serology was reported in 175 (46.7%) recipients and 188 (50.1%) donors. However, EBV serology status at the time of KT was unknown in 116 (30.9%) recipients and 181 (48.3%) donors. Even in eras 2 and 3 when calcineurin inhibitors were used, EBV serology status at the time of KT was unknown in 22 (8.2%) recipients and 76 (28.2%) donors. EBV serology at the time of KT in patients who developed PTLD was negative in six and positive in three. EBV serology of the donor was not available in three cases, while the combination of an EBV-negative
recipient and an EBV-positive donor was discovered in five cases (56%). EBV serology of the recipient at the time of PTLD occurrence was positive in 60% of cases. Patient 2 underwent emergency surgery for gastrointestinal perforation but died of postoperative disseminated intravascular coagulation. Histopathology of the entire intestinal layer at the perforation site showed ulceration of the mucosal surface and cellular infiltration from the submucosa to the muscular layer, mainly of atypical lymphocytes, consistent with PTLD. Since EBV-DNA was identified in the tissue of the perforated small intestine, a diagnosis of gastrointestinal PTLD due to EBV infection was made. Despite treatment, two patients (22%) died due to PTLD. Graft loss occurred in case 1 2 years after PTLD treatment, and occurred in case 5 due to vascular injury during resection of the ileocecal tumor. The graft survival rate after treatment for PTLD was 44% during the follow-up period.

The overall graft survival rates of the cancer and non-cancer groups were 95% and 91% at 1 year, 81% and 84% at 5 years, 56% and 75% at 10 years, 37% and 63% at 15 years, and 25% and 53% at 20 years, respectively. The graft survival rate of recipients with cancer was significantly lower than that of recipients without cancer (log-rank: $P < 0.05$, Wilcoxon: $P < 0.01$). The overall patient survival rates in the cancer group were 95%, 91%, 91%, 84%, and 84% at 1, 5, 10, 15, and 20 years after KT, respectively. Patient survival rates were not significantly different between the two groups. (log-rank: $P = 0.19$, Wilcoxon: $P = 0.39$).

After 6329.9 person-years of follow-up, the median follow-up duration was 15.4 years (IQR 10.3–22.5). Five patients died due to malignancy. The mortality rate per 1000 patient-years was 0.79 (95% CI 0.38, 1.85). The cause of death was hepatocellular carcinoma in one patient, squamous cell carcinoma in the transplanted kidney in one patient, malignant schwannoma in one patient, and EBV-related lymphoma in two patients. Of these, three patients died with a functioning graft. Nine patients had PTLD, with a median age of 9.8 years (IQR, 6.8–13.8 years). Two patients (one with gastrointestinal PTLD and one with T/NK-cell PTLD) died after diagnosis because of unresponsiveness to treatment. According to the Cox proportional hazards model, we assessed the variables related to the incidence of malignancy. Multivariate analysis identified era 3 versus era 1 (hazard ratio 2.20, 95% confidence interval 1.31–3.69) and era 3 versus era 2 (hazard ratio 2.27, 95% confidence interval 1.42–3.63) as independent risk factors for incidence of malignancy at 10 years post-transplantation (Table 4).

Table 1

| Variable                                      | Cancer (n = 21) | Non-cancer (n = 354) | P-value |
|-----------------------------------------------|-----------------|----------------------|---------|
| Recipient age, years, median, [IQR]           | 11.3 [6.6–14.7] | 9.5 [5.7–12.8]       | 0.15    |
| Sex of recipient, male, n (%)                 | 7 (33.3)        | 205 (57.9)           | 0.04    |
| Number of re-transplants, n (%)               | 5 (23.8)        | 49 (13.8)            | 0.20    |
| Preemptive KT, n (%)                          | 2 (9.5)         | 27 (7.6)             | 0.67    |
| Duration of dialysis, months, median, [IQR]   | 12.9 [6.4–26.9] | 19.8 [10.3–40.7]     | 0.10    |
| Donor age, years, median, [IQR]               | 38 [32–41]      | 39 [35–44]           | 0.16    |
| Sex of donor, male, n (%)                     | 5 (23.8)        | 138 (39.0)           | 0.25    |
| Living related donor, n (%)                   | 17 (81.0)       | 337 (95.2)           | 0.02    |
| ABO-incompatible, n (%)                       | 0 (0)           | 30 (8.5)             | 0.40    |
| Primary immunosuppression, n (%)              |                 |                      |         |
| Cyclosporine                                  | 5 (23.8)        | 180 (50.8)           | 0.02    |
| Tacrolimus                                    | 8 (38.1)        | 75 (21.2)            | 0.10    |
| Azathioprine or mizoribine                    | 13 (61.9)       | 256 (72.3)           | 0.46    |
| Mycophenolate mofetil                         | 8 (38.1)        | 98 (27.7)            | 0.32    |
| Transplant era, n (%)                         |                 |                      |         |
| Era 1 (1975–1985)                             | 8 (38.1)        | 97 (27.4)            | 0.32    |
| Era 2 (1986–2001)                             | 5 (23.8)        | 149 (42.1)           | 0.11    |
| Era 3 (2002–2009)                             | 8 (38.1)        | 108 (30.5)           | 0.47    |
| Acute rejection within 1 year after KT, n (%) | 12 (57.1)       | 211 (59.6)           | 0.82    |
| Graft loss, n (%)                             | 14 (66.7)       | 146 (41.2)           | 0.04    |
| Follow-up period, years, median, [IQR]        | 15.2 [10.6–29.6]| 15.5 [10.3–22.4]     | 0.46    |

IQR interquartile range, KT kidney transplantation
**Discussion**

Malignancy after pediatric KT is a serious complication that affects morbidity and mortality. In this study, the overall incidence of PTM in our population was 5.6%, which is lower than that in patients in other countries [12–15]. The cumulative cancer incidence after pediatric KT has been reported to be 4–7% by 10 years [12, 15], 13–20% by 20 years [13–15], and 26–41% by 30 years [13, 15], which was higher than that in our study.

In contrast to adults, malignancies other than PTLD are rare in children. According to a report published by the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) [16], of the 12,189 pediatric patients who received transplants from 1987 to 2013, 311 (2.55%) developed post-transplant malignancies, of which 262 (84.5%) had lymphoproliferative diseases. As for malignancies other than lymphoproliferative diseases, skin cancer is most common, although cancers of various organs, sarcoma, melanoma, and neuroblastoma have been reported. Regarding the type of malignancy, the most common solid cancers in our series were hepatitis virus-related hepatocellular carcinoma and breast cancer; in contrast to other studies, there were no skin cancers. The type of solid cancer was very different from those reported in Europe, Austria, and the United States [11–14]. In our study, we also encountered sarcoma and liver cancer until the early 1980s. The reasons for this may include immunosuppression, mainly with steroids and metabolic antagonists, and the large number of hepatitis virus (HBV, HCV)-positive patients due to blood transfusion. The lower incidence of skin cancer may be at least partly explained by population and environmental differences in cancer risk. Furthermore, the incidence of childhood cancer in the Japanese population is lower than that in other countries, e.g., England; this is thought to be due to racial differences and genetic factors [17]. Therefore, it is possible that the incidence of solid cancers after pediatric KT may also be lower in Japan than in other countries.

The median time to cancer development after pediatric KT varied by cancer type. PTLD developed early after transplantation, while solid tumors developed mostly after the transition to adulthood. Francis et al. [14] reported two peaks in the time to cancer for non-skin cancers, with a median of 6.6 years for PTLD and a median of 14.8 years for other

---

**Table 2** Characteristics of the individual patients with solid cancer

| Case | Age at KT (years) | Sex | Primary disease | Duration of dialysis (months) | Number of KTs | Immunosuppression* | Type of malignancy | Time to diagnosis of cancer after KT (years) | Prognosis |
|------|------------------|-----|-----------------|-----------------------------|---------------|-------------------|-------------------|---------------------------------------------|----------|
| 1    | 16.5             | M   | CGN             | 5                           | 1             | MP, AZA           | Liver cancer (HBV) | 12.4                                        | Dead     |
| 2    | 16.8             | F   | Hypo/dys        | 2                           | 3             | MP, AZA           | Squamous cell carcinoma (transplanted kidney) | 28.5                                        | Dead     |
| 3    | 16.7             | F   | CGN             | 30                          | 1             | MP, AZA           | Bladder cancer     | 26.0                                        | Alive    |
| 4    | 7.1              | F   | FSGS            | 3                           | 1             | MP, AZA           | Malignant schwannoma | 25.3                                        | Dead     |
| 5    | 5.5              | M   | Hypo/dys        | 7                           | 1             | MP, AZA           | Liver cancer (HBV) | 15.8                                        | Alive    |
| 6    | 9.0              | M   | RPGN            | 15                          | 2             | MP, AZA           | Testicular cancer  | 29.8                                        | Alive    |
| 7    | 15.0             | F   | FSGS            | 13                          | 1             | MP, AZA           | Bladder leiomyosarcoma | 3.3                                         | Alive    |
| 8    | 11.3             | M   | Hypo/dys        | 7                           | 2             | MP, AZA, MZ, AZA, ALG | Liver cancer (HCV) | 29.9                                        | Alive    |
| 9    | 14.0             | F   | FSGS            | 11                          | 1             | CyA, MP, AZA      | Cervical cancer    | 26.0                                        | Alive    |
| 10   | 14.0             | F   | RPGN            | 0                           | 2             | CyA, MP, AZA, ALG | Breast cancer      | 19.3                                        | Alive    |
| 11   | 15.7             | F   | FSGS            | 16                          | 1             | Tac, MP, MMF, BLX | Breast cancer      | 12.0                                        | Alive    |
| 12–1 | 14.2             | F   | Denys–Drash     | 9                           | 1             | CyA, MP, MMF, BLX | Wilms tumor (mediastinal lymph node metastasis) | 4.8                                         | Alive    |
| 12–2 |                 |     |                 |                             |               |                   | Wilms tumor (lung metastases)                  | 7.2                                         |         |

*ALG antilymphocyte globulin, AZA azathioprine, BLX basiliximab, CGN chronic glomerulonephritis, CyA cyclosporine, F female, FSGS focal segmental glomerulosclerosis, Hypo/dys hypoplastic/dysplastic kidney, HBV hepatitis B virus, HCV hepatitis C virus, KT kidney transplantation, M male, MMF mycophenolate mofetil, MP methylprednisolone, MZ mizoribine, Tac tacrolimus, RPGN rapidly progressive glomerulonephritis

*Primary kidney transplant
| Case | Age at KT (years) | Sex | Primary disease | Immunosuppression | EBV serology at KT (recipient/donor) | EBV status of PTLD | Pathology/subtype | Time to diagnosis of cancer after KT | Symptoms | Localization | Treatment | Prognosis |
|------|------------------|-----|----------------|-------------------|---------------------------------------|-------------------|------------------|------------------------------------|----------|-------------|-----------|----------|
| 1    | 15.6             | M   | MPGN           | CyA, MP, AZA      | P/NA                                  | EBV negative      | DLBCL            | 14.8 years                        | Abdominal pain | Colon, mesenteric lymph nodes | RI, surgery, chemotherapy | Alive    |
| 2    | 9.1              | F   | HUS            | Tac, MP, MZ       | N/P                                   | EBV positive      | Unclassifiable   | 4 months                         | Fever, upper abdominal pain | Gastroduodenal, small intestine | RI, antiviral drug, IVIG | Dead     |
| 3    | 2.8              | M   | Hypo/dys       | Tac, MP, MZ       | N/P                                   | EBV positive      | Early lesion     | 7 months                         | Vomiting, diarrhea, melena | Colon, mesenteric lymph nodes | RI, antiviral drug | Alive    |
| 1–1  | 9.8              | F   | Hypo/dys       | Tac, MP, MMF      | P/NA                                  | EBV positive      | Early lesion     | 1.8 years                        | Fever, vomiting, diarrhea | Colon, mesenteric lymph nodes | RI, antiviral drug, IVIG | Alive    |
| 4–2  |                  |     |                | EBV negative      | Early lesion                         | 8.3 years         | Fever of unknown origin | Colon | RI, R, chemotherapy | | |
| 5    | 12.7             | M   | FSGS           | Tac, MP, MMF, BLX | P/P                                   | EBV negative      | Burkitt lymphoma | 8.1 years                        | Abdominal mass | Colon | RI, R, surgery, chemotherapy | Alive    |
| 6    | 11.0             | F   | Hypo/dys       | CyA, MP, MMF, BLX | N/P                                   | EBV positive      | Early lesion     | 2.8 years                        | Upper abdominal pain | Colon, mesenteric lymph nodes | RI | Alive    |
| 7    | 4.3              | F   | Hypo/dys       | Tac, MP, MMF, BLX | N/P                                   | EBV positive      | Monomorphic, T-/NK-cell | 2.3 years                        | Fever, abdominal pain, diarrhea | Lymph nodes (neck, mediastinal, mesenteric) | RI, chemotherapy | Dead     |
| 8    | 3.8              | M   | Cortical necrosis | Tac, MP, MMF, BLX | N/NA                                  | EBV positive      | Polymorphic      | 3 months                         | Melena | Gastroduodenal, lymph nodes in porta hepatitis | RI, R, chemotherapy | Alive    |
| 9    | 6.0              | F   | Hypo/dys       | Tac, MP, MMF, BLX | N/P                                   | EBV positive      | Early lesion     | 2.2 years                        | Diarrhea, lymphadenopathy | Colon, lymph nodes (neck, inguinal) | RI, R | Alive    |

AZA azathioprine, BLX basiliximab, CyA cyclosporine, DLBCL diffuse large B-cell lymphoma, EBV Epstein-Barr virus, F female, FSGS focal segmental glomerulosclerosis, HUS hemolytic uremic syndrome, Hypo/dys hypoplastic/dysplastic kidney, IVIG intravenous immunoglobulin, KT kidney transplantation, M male, MMF mycophenolate mofetil, MP methylprednisolone, MPGN membranoproliferative glomerulonephritis, MZ mizoribine, NA not available, N negative, P positive, PTLD post-transplant lymphoproliferative disorders, RI reduction of immunosuppression, R rituximab, Tac tacrolimus

*Primary kidney transplant
cancers, which are similar to the findings in our study. This suggests that surveillance for PTM associated with pediatric KT should focus on PTLD during the first decade after KT, and that adult-type cancers should be included in the differential diagnosis thereafter.

Recent reports have shown that transplant recipients have a higher risk of death from cancer than do other patients with cancer [18]. In a study of pediatric solid organ transplant recipients, 23% of deaths were due to malignancy, and 68% of cancers causing death were PTLD [19]. Additionally, a study of pediatric kidney transplant recipients reported that 64% of deaths were due to cancer [15]. The impact of PTM on the graft has been debated, and no definitive opinion has been reached. Serrano et al. [15] reported that the hazard ratios for both death and graft loss were higher in patients with PTM than in those without PTM, whereas Francis et al. [20] reported that the development of PTM was associated only with death and not with graft loss. In our study, four of the patients with PTM died with a functioning graft, and one surviving patient progressed to kidney failure because of chronic allograft nephropathy after PTM treatment. The Kaplan–Meier curve showed a significant difference in graft survival of patients with PTM compared to patients without PTM, but no significant difference in patient survival. In our study, we were also unable to demonstrate the impact of PTM development on allografts.

PTLD is the most common malignancy observed after pediatric KT. The incidence of PTLD is higher in pediatric KT recipients than in adult KT recipients, and is seen in 2–4% of pediatric KT patients at a median of 14.9 months from transplant [7]. The major risk factors for the development of PTLD are the degree of T-cell immunosuppression and the EBV serological status of the recipient [7–9]. PTLD is an EBV-positive B-cell proliferation that occurs in immunosuppressed patients and reduces T-cell immune surveillance. Because EBV-infected B cells are normally suppressed by cytotoxic T-cells, PTLD may develop when T-cell immunity is compromised. The relationship between immunosuppression after pediatric KT and the risk of developing PTLD has been shown to increase with an increase in the degree of immunosuppression in patients receiving induction therapy or long-term high-dose Tac [21–23]. In our study, we investigated risk factors for the incidence of malignancy up to 10 years after KT and identified era3 using Tac and MMF as independent risk factors. Therefore, it was suggested that the recent immunosuppressive therapy has an impact on the incidence of malignancy (especially on the incidence of PTLD). In the present study, most pediatric KT patients who developed PTLD were treated with Tac and MMF. In addition, more than 50% of patients were treated for AR within 1 year after KT, suggesting that they were in a state of over-immunosuppression. The highest-risk group comprises EBV-naive recipients transplanted with kidneys from EBV-positive donors, and the cause of PTLD in more than 90% of pediatric cases is the proliferation of EBV-positive B cells [18]. In our study, EBV serology of the recipient at the time of PTLD occurrence was positive in 60% of cases, but we could not investigate further because little donor serological information was available. In previous reports, donor positivity/recipient negativity (hazard ratio 7.7, 95% CI 1.6–35.9) was a risk factor for PTLD in EBV serotypes [21]. Therefore, pediatric patients with KT are generally considered to be at a higher risk of developing PTLD because of the higher pre-transplant EBV seronegative rate in children.

Recently, regular monitoring of EBV viral load and early recognition of recipients at high risk for PTLD has been considered a clinical priority [24]. Previous studies have shown that elevated EBV-DNA levels and persistently high EBV load are risk factors for PTLD [25, 26], but no clear cut-off EBV load for prediction of the development of PTLD has been determined. However, EBV-DNA levels should be

### Table 4

| Variable                        | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | HR 95% CI P-value   | HR 95% CI P-value     |
| Recipient age (years)           | 0.99 0.97 1.01 0.30  |                       |
| Sex of recipient (male)         | 0.90 0.73 1.11 0.33  |                       |
| Sex of donor (male)             | 0.98 0.79 1.21 0.86  |                       |
| Living related donor            | 0.84 0.53 1.33 0.45  |                       |
| Tac versus CyA                   | 1.14 0.89 1.47 0.31  |                       |
| MMF versus AZA or MZ            | 1.26 1.00 1.59 <0.01 |                       |
| Transplant era                   |                     |                       |
| Era 3 versus Era 1              | 1.38 1.06 1.81 <0.01 | 2.20 1.31 3.69 <0.01  |
| Era 3 versus Era 2              | 1.56 1.22 1.99 <0.01 | 2.27 1.42 3.63 <0.01  |
| Graft loss                       | 1.13 0.89 1.43 0.31  |                       |

AZA azathioprine, CI confidence interval, CyA cyclosporine, HR hazard ratio, MMF mycophenolate mofetil, MZ mizoribine, Tac tacrolimus
monitored regularly in patients at high risk for PTLD, as they indicate EBV infection and/or reactivation, detected as an increase in EBV-DNA in the peripheral blood preceding PTLD. Regarding monitoring intervals, since most cases of EBV-positive PTLD develop early after KT, it is reasonable to monitor high-risk patients frequently in the early post-KT period and to increase the monitoring interval as the time after KT increases. The decision to reduce the frequency of EBV monitoring after KT must be made on an individual basis, considering many factors, including the type of graft, degree of ongoing immunosuppression, and EBV viral load.

The present study has numerous limitations due to the retrospective nature of the study and its single-center design. First, our study had a small sample size, and the heterogeneity of our cohort potentially limits the generalizability of our findings. Second, maintenance therapy for immunosuppression has changed over time, and conclusions about long-term cancer risk cannot be drawn solely from protocols for induction therapy for immunosuppression. In addition, there were several cases of unknown EBV serology among the recipients and donors, and the relationship between EBV serology and the development of PTLD could not be shown. Finally, the management and surveillance of transplant immunity and oncology has changed over a short period, and given the long duration of the study, there are limitations to this study that are influenced by time. The best way to address this issue would be to perform a multicenter, prospective study rather than a single-center, retrospective study.

Conclusions

In this study, we reported the long-term results of the incidence of malignancy after pediatric KT in Japanese patients at a single center. KT is the treatment of choice for children with CKD because it provides the best opportunities for growth, development, and quality of life. In recent years, the results of pediatric KT have improved dramatically owing to improvements in perioperative and postoperative care, immunosuppressive medications, and infection surveillance and management. However, malignancy after KT is a serious post-transplant complication, and the long-term risk of malignancy increases significantly after KT. Therefore, the occurrence of malignancy after pediatric renal transplantation is an important factor in mortality. Regular surveillance after KT should be strengthened, and continued vigilance for detection of malignancy following KT is necessary.

Acknowledgements We also thank Editage (www.editage.com) for editing the draft of this manuscript.

Author contributions YA and SH designed the study. HR, HR, MM and YH contributed to the acquisition and analysis of the data. HH, KI, SS and KS contributed to the interpretation of the data, and critically revised the manuscript. The first draft of the manuscript was written by YA and all authors verified and contributed to the revision of all drafts of the manuscript. All authors approved this final draft of the manuscript.

Funding We received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors for the purpose of this research.

Declarations

Conflict of interest Yuko Hamaaki belongs to an endowed department sponsored by Asahi Kasei Pharma Corporation, Novartis Pharma K.K., Chugai Pharmaceutical Co., and Astellas Pharma (until 28/Feb/2018). Seiichiro Shishido belongs to an endowed department sponsored by Asahi Kasei Pharma Corporation, Novartis Pharma K.K., and Chugai Pharmaceutical Co. The other authors have no potential conflicts of interest to disclose.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number H29b-91) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent The requirement for informed consent was waived by the ethics committee.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. McDonald SP, Craig JC. Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med. 2004;350:2654–62.
2. Chesnaye N, Bonthuis M, Schaefer F, Groothoff JW, Verrina E, Heaf JG, et al. Demographics of paediatric renal replacement therapy in Europe: a report of the ESPN/ERA–EDTA registry. Pediatr Nephrol. 2014;29(12):2403–10.
3. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant. 2007;7:2140–51.
4. Coutinho HM, Groothoff JW, Offringa M, Gruppen MP, Heymans HS. De novo malignancy after paediatric renal replacement therapy. Arch Dis Child. 2001;85:478–83.
5. Smith JM, Martz K, Blydt-Hansen TD. Pediatric kidney transplant practice patterns and outcome benchmarks, 1987–2010: a report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatr Transplant. 2013;17:149–57.
6. Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, et al. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2014;85:1395–403.
7. Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol. 2009;24:731–6.
8. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8:173–83.
9. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 date report. Am J Transplant. 2012;12(Suppl 1):30
10. Aoki Y, Hamasaki Y, Satoh H, Matsui Z, Muramatsu M, Hamada R, et al. Long-term outcomes of pediatric kidney transplantation: a single-center experience over the past 34 years in Japan. Int J Urol. 2020;27:172–8.
11. Shishido S, Hasegawa A. Current status of ABO-incompatible kidney transplantation in children. Pediatr Transplant. 2005;9:148–54.
12. Koukourgianni F, Harambat J, Ranchin B, Euvrard S, Bouvier R, Liutkus A, et al. Malignancy incidence after renal transplantation in children: a 20-year single-centre experience. Nephrol Dial Transplant. 2010;25:611–6.
13. Ploos van Amstel S, Vogelzang JL, Starink MV, Jager KJ, Groothoff JW. Long-term risk of cancer in survivors of pediatric ESRD. Clin J Am Soc Nephrol. 2015;10:2198–204.
14. Francis A, Johnson DW, Craig JC, Wong G. Incidence and predictors of cancer following kidney transplantation in childhood. Am J Transplant. 2017;17:2650–8.
15. Serrano OK, Bangdiwala AS, Vock DM, Chinnakotla S, Dunn TB, Finger EB, et al. Post-transplant malignancy after pediatric kidney transplantation: retrospective analysis of incidence and risk factors in 884 patients receiving transplants between 1963 and 2015 at the University of Minnesota. J Am Coll Surg. 2017;225:181–93.
16. North American Pediatric Renal Trials and Collaborative Studies. In NAPRTCS 2014 Annual Report. https://naprtcs.org/system/files/2014_Annual_Transplant_Report.pdf. Accessed 15 Jan 2020.
17. Nakata N, Ito Y, Magadi W, Bonaventure A, Stiller CA, Katanoda K, et al. Childhood cancer incidence and survival in Japan and England: a population-based study (1993–2010). Cancer Sci. 2018;109:422–34.
18. D’Arcy ME, Coghill AE, Lynch CF, Koch LA, Li J, Pawlish KS, et al. Survival after a cancer diagnosis among solid organ transplant recipients in the United States. Cancer. 2019;125:933–42.
19. Kitchlu A, Dixon S, Dirk JS, Chanchlani R, Vasilevska-Ristovska J, Borges K, et al. Elevated risk of Cancer following solid organ transplantation in childhood: a population-based cohort study. Transplantation. 2019;103:588–96.
20. Francis A, Johnson DW, Craig J, Teixeira-Pinto A, Wong G. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients. Kidney Int. 2018;94:809–17.
21. McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8:984–9.
22. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–30.
23. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006;81:1227–33.
24. Dharnidharka VR. Peripheral blood Epstein-Barr viral nucleic acid surveillance as a marker for posttransplant cancer risk. Am J Transplant. 2017;17:611–6.
25. Le J, Durand CM, Agha I, Brennan DC. Epstein-Barr virus and renal transplantation. Transplant Rev (Orlando). 2017;31:55–60.
26. Colombini E, Guzzo I, Motolli F, Longo G, Russo C, Lombardi A, et al. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients. Pediatr Nephrol. 2017;32:1433–42.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.